303 related articles for article (PubMed ID: 18723477)
21. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
22. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
23. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
Moriya S; Che XF; Komatsu S; Abe A; Kawaguchi T; Gotoh A; Inazu M; Tomoda A; Miyazawa K
Int J Oncol; 2013 May; 42(5):1541-50. PubMed ID: 23546223
[TBL] [Abstract][Full Text] [Related]
24. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Fribley A; Zeng Q; Wang CY
Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
[TBL] [Abstract][Full Text] [Related]
26. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
27. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
28. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
Selimovic D; Porzig BB; El-Khattouti A; Badura HE; Ahmad M; Ghanjati F; Santourlidis S; Haikel Y; Hassan M
Cell Signal; 2013 Jan; 25(1):308-18. PubMed ID: 23079083
[TBL] [Abstract][Full Text] [Related]
30. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
Feng R; Ma H; Hassig CA; Payne JE; Smith ND; Mapara MY; Hager JH; Lentzsch S
Mol Cancer Ther; 2008 Jun; 7(6):1494-505. PubMed ID: 18566220
[TBL] [Abstract][Full Text] [Related]
31. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells.
Yeung BH; Huang DC; Sinicrope FA
J Biol Chem; 2006 Apr; 281(17):11923-32. PubMed ID: 16446371
[TBL] [Abstract][Full Text] [Related]
32. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Escalante AM; McGrath RT; Karolak MR; Dorr RT; Lynch RM; Landowski TH
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1567-76. PubMed ID: 23572175
[TBL] [Abstract][Full Text] [Related]
33. [Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].
Yang Y; Dong HJ; Gao GX; Wang YW; Gu HT; Shu MM; Zhu HF; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1177-80. PubMed ID: 21129256
[TBL] [Abstract][Full Text] [Related]
34. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Chauhan D; Singh A; Brahmandam M; Podar K; Hideshima T; Richardson P; Munshi N; Palladino MA; Anderson KC
Blood; 2008 Feb; 111(3):1654-64. PubMed ID: 18006697
[TBL] [Abstract][Full Text] [Related]
35. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
[TBL] [Abstract][Full Text] [Related]
37. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Dunner K; Huang P; Abbruzzese JL; McConkey DJ
Cancer Res; 2005 Dec; 65(24):11658-66. PubMed ID: 16357177
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
40. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
Hu J; Dang N; Menu E; De Bruyne E; Xu D; Van Camp B; Van Valckenborgh E; Vanderkerken K
Blood; 2012 Jan; 119(3):826-37. PubMed ID: 22128141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
